Krystal Biotech (KRYS)
NASDAQ:KRYS

Krystal Biotech (KRYS) Stock Price & Analysis

263 Followers

KRYS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$47.67 - $85.65
Previous Close$80.21
Volume120.91K
Average Volume (3M)175.74K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$394.42M
Total Debt (Recent Filing)$9.12M
Price to Earnings (P/E)-15.4
Beta0.17
Next EarningsMar 14, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-5.21
Shares Outstanding25,747,647
R-Squared0.08
Standard Deviation0.16
10 Day Avg. Volume149,583
30 Day Avg. Volume175,744
Price to Book (P/B)3.96
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-17.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside33.21% Upside
Rating ConsensusStrong Buy
Alpha0.04
Number of Analyst Covering5


Financials

Annual

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

KRYS FAQ

What was Krystal Biotech’s price range in the past 12 months?
Krystal Biotech lowest stock price was $47.67 and its highest was $85.65 in the past 12 months.
    What is Krystal Biotech’s market cap?
    Currently, no data Available
    When is Krystal Biotech’s upcoming earnings report date?
    Krystal Biotech’s upcoming earnings report date is Mar 14, 2023 which is in 35 days.
      How were Krystal Biotech’s earnings last quarter?
      Krystal Biotech released its earnings results on Nov 07, 2022. The company reported -$1.17 earnings per share for the quarter, beating the consensus estimate of -$1.188 by $0.018.
        Is Krystal Biotech overvalued?
        According to Wall Street analysts Krystal Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Krystal Biotech pay dividends?
          Krystal Biotech does not currently pay dividends.
          What is Krystal Biotech’s EPS estimate?
          Krystal Biotech’s EPS estimate is -$1.26.
            How many shares outstanding does Krystal Biotech have?
            Krystal Biotech has 25,747,646 shares outstanding.
              What happened to Krystal Biotech’s price movement after its last earnings report?
              Krystal Biotech reported an EPS of -$1.17 in its last earnings report, beating expectations of -$1.188. Following the earnings report the stock price went up 6.611%.
                Which hedge fund is a major shareholder of Krystal Biotech?
                Among the largest hedge funds holding Krystal Biotech’s share is Deerfield Management Company, LP. It holds Krystal Biotech’s shares valued at 12M.

                  ---

                  Krystal Biotech Stock Smart Score

                  9
                  Outperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  The Krystal Biotech stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Krystal Biotech

                  Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Relay Therapeutics
                  Akero Therapeutics
                  ProKidney
                  ImmunityBio
                  Revolution Medicines

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis